Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic.
J Int Med Res
; 48(10): 300060520966151, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-894958
ABSTRACT
OBJECTIVE:
No data are available to develop uniform recommendations for reperfusion therapies in ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to fill the evidence gap regarding STEMI reperfusion strategy during the COVID-19 era.METHODS:
Clinical characteristics and outcomes for 17 patients with STEMI who received fibrinolysis during the COVID-19 pandemic were compared with 20 patients who received primary percutaneous coronary intervention (PPCI), and were further compared with another 41 patients who received PPCI in the pre-COVID-19 period.RESULTS:
In patients with STEMI, fibrinolysis achieved a comparable in-hospital and 30-day primary composite end point, as compared with those who received PPCI during the COVID-19 pandemic. No major bleeding was detected in either group. Compared patients with STEMI who received PPCI in the pre-COVID-19 period, we found a remarkable extension of chest pain onset-to-first medical contact (FMC) and FMC-to-wire crossing times, significantly increased number and length of stents, and much worse thrombolysis in myocardial infarction flow in patients with STEMI who received PPCI during the COVID-19 pandemic.CONCLUSION:
Owing to its considerable efficacy and safety and advantages in conserving medical resources, we recommend fibrinolysis as a reasonable alternative for STEMI care during the COVID-19 pandemic.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Urokinase-Type Plasminogen Activator
/
Coronavirus Infections
/
Pandemics
/
Fibrinolytic Agents
/
ST Elevation Myocardial Infarction
Type of study:
Observational study
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Int Med Res
Year:
2020
Document Type:
Article
Affiliation country:
0300060520966151
Similar
MEDLINE
...
LILACS
LIS